INSP | Ticker Profile - Titan Protect

INSP

Inspire Medical Systems, Inc.

Healthcare · Medical Devices · NYQ

$41.19

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 100.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$1.2B

Total market value of the company

Trailing P/E

9.60

Very cheap relative to earnings

Forward P/E

32.34

Based on estimated future earnings — lower means cheaper

Rev Growth

+1.6%

Year-over-year revenue change

Profit Margin

14.3%

How much profit the company keeps from each dollar of revenue

ROE

18.4%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$53.00

+29% from current price — median analyst estimate

Recommendation

HOLD

Consensus view from 12 analysts covering this stock

About Inspire Medical Systems, Inc.

Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for patients with moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.

https://www.inspiresleep.com

Country: United States Employees: 1,333 Industry: Medical Devices

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

-0.647

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0686

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.594

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-48.4%

Historical annualised return based on price data

Max Drawdown

-81.5%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.83

Less volatile than the market — more defensive

52W High

$147.03

72% below the year high

52W Low

$39.61

4% above the year low

Avg Volume

1,125,644

Average daily shares traded — higher means easier to buy and sell

Short Ratio

3.0

Days it would take all short sellers to cover — higher means more crowded

Short % Float

16.7%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$4.40

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

3.73

Heavy leverage — higher financial risk if revenues decline

Current Ratio

6.34

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

4.35

Like current ratio but excludes inventory — stricter test

Gross Margin

85.8%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-0.5%

Profit from core operations before interest and tax

Free Cash Flow

$86M

Positive — the business generates more cash than it spends

Revenue (TTM)

$915M

Total revenue over the last 12 months

Net Income

$131M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$65.00

Target Median

$53.00

Target Low

$39.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go